[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-disease-requiring-hemodialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-disease-requiring-hemodialysis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,70,96,132,154,181,203,228,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100624721","benefits-of-a-renal-rehabilitation-program-adapted-to-uremic-patients-on-daily-hemodialysis-at-low-dialysate-flow-rate-100624721",false,"NCT07413315","Benefits of a Renal Rehabilitation Program Adapted to Uremic Patients on Daily Hemodialysis at Low Dialysate Flow Rate.","Inclusion Criteria:\n\n* patient with terminal chronic kidney disease requiring hemodialysis treatment\n* patient recently hospitalized for an acute medical event.\n\nExclusion Criteria:\n\n* dementia\u002Fmild cognitive impairment (MMSE \\\u003C 20\u002F30)\n* decompensated psychiatric pathology and\u002For behavioral disorders\n* pregnant woman\n* recovery of renal function allowing interruption of helodialysis sessions\n* candidate for neurological rehabilitation\n* patient with recent spinal cord injury\n* patient with absolute and\u002For relative contraindication to performing a stress test\n* severe or poorly tolerated cardiac rhythm disorder\n* severe or symptomatic obstruction to left ventricular ejection\n* decompensated heart failure\n* acute myocarditis, pericarditis or endocarditis\n* acute aortic dissection\n* high-risk emboligenic intracardiac thrombus\n* significant stenosis of the common trunk\n* ventricular aneurysm\n* supraventricular tachycardia with poorly controlled ventricular rate, acquired high-degree or complete block\n* obstructive cardiomyopathy with high resting gradient\n* recent stroke or TIA\n* acute venous thrombosis with or without pulmonary embolism\n* poorly controlled clinical condition, such as marked anemia, significant electrolyte disturbance, hyperthyroidism, etc.\n* lack of cooperation from the patient\n* Blood pressure \\> 200\u002F110 mmHg","ALL","18 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"NA","The concept of renal rehabilitation has become increasingly important with the increasing age of patients with severe or even terminal chronic kidney disease (CKD). It combines physical exercise and nutritional monitoring programs for patients with terminal CKD who are most often treated with conventional hemodialysis (HD) at a rate of 3 sessions of 4 hours per week.\n\nSarcopenia is a very common phenomenon in patients with CKD. The prevalence found in recent meta-analyses varies between 25.6 and 28.5% in patients treated with dialysis. It is even higher in patients treated with HD than in patients treated with peritoneal dialysis (PD). Younger and more active patients will more often choose PD. The conventional HD modality preserves residual renal function less well, which is important for better elimination of uremic toxins bound to plasma proteins. Conventional HD requires a higher immobilization time and causes more post-dialysis symptoms, leaving less time for the patient to be physically active.\n\nThe phenomenon of sarcopenia is not insignificant. It is associated in dialysis patients with a higher mortality rate (risk x 1.8) and a higher incidence of cardiovascular events (risk x 3.8). The association with higher mortality is well demonstrated for the 2 main components of sarcopenia, namely reduced muscle mass and reduced muscle strength. Sarcopenia also increases the risk of falls and fractures, it decreases the physical performance of patients and their ability to perform activities of daily living. The quality of life of patients is reduced and the probability of social placement is high.\n\nThe phenomena of sarcopenia and physical deconditioning are even more problematic in patients in HD after an acute medical problem. The need for rehabilitation is even higher. \"Classical\" HD treatment can be a burden for these patients, leaving no room for integrating a complete rehabilitation program.\n\nDaily low dialysate flow rate hemodialysis (LDF) is a type of hemodialysis in which patients benefit from more frequent but shorter and hemodynamically better tolerated HD sessions. This new technique potentially presents certain advantages over conventional HD, particularly at the cardiovascular level: better blood pressure control and better reduction of left ventricular hypertrophy. LDF also allows better control of hyperphosphatemia with a reduced need for phosphorus binders. Thanks to more frequent dialysis (5 to 6 sessions per week), inter-dialytic weight gain is often less significant, allowing less aggressive ultrafiltration, with better hemodynamic tolerance, and better post-dialysis recovery. In this perspective, this study aims to examine the interest of integrating HDQ dialysis into a renal rehabilitation program in patients with terminal CKD whose dialysis must continue after an acute event requiring hospitalization. The investigators want to study whether this technique allows the implementation of a more effective rehabilitation program, while maintaining the same dialysis efficiency as with the conventional HD technique. To the investigator's knowledge, no study concerning patients under HDQ has been conducted during their renal rehabilitation phase.\n\nThe objectives of the current study are:\n\n* To study the interest of integrating HDQ dialysis into a renal rehabilitation program in patients with terminal CKD.\n* To study the efficacy and tolerance of HDQ dialysis and the rehabilitation program in these patients.",[25,26,27],"Chronic Kidney Disease Requiring Hemodialysis","Sarcopenia","Rehabilitation Program","RECRUITING","2026-02-09",{"date":31,"type":32},"2026-02-17","ACTUAL",{"date":34,"type":32},"2024-08-13",{"date":36,"type":19},"2027-12-31",{"name":38,"class":39},"Brugmann University Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":20,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100591261","technology-assisted-collaborative-care-intervention-to-improve-patient-centered-outcomes-in-dialysis-patients-100591261","NCT06978127","Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients","Technology Assisted Collaborative Care Intervention (TĀCcare) 2.0 Implementation Trial to Improve Patient-centered Outcomes in Patients on Hemodialysis","TACcare 2 0","Eligibility Criteria:\n\n1. age 18 years or older;\n2. undergoing thrice-weekly maintenance hemodialysis (HD) for \\> 3 months;\n3. English or Spanish speaking;\n4. able to provide informed consent\n\nIneligibility Criteria:\n\n1. active thought disorder, delusions or active suicidal ideation\n2. active substance abuse\n3. enrolled in hospice or life expectancy \\\u003C 6 months (based on clinician's judgement)\n4. too ill or cognitively impaired to participate based on renal provider's judgement\n5. living kidney transplant scheduled in \\\u003C3 months\n6. undergoing active cancer treatment.\n7. enrolled in another research study\n8. plan to transition to home dialysis within 3 months\n9. plan to move to another dialysis facility within 3 months",{"count":50,"type":19},424,[22],"The goal of this study is to learn if a collaborative care intervention of pharmaco-therapy and\u002For cognitive behavioral therapy (CBT), delivered in a real-world setting, improves symptoms of pain, fatigue and\u002For depression.",[25],[55,56,57,58,59],"Chronic Kidney Disease","Hemodialysis","Pain","Depression","Fatigue","2026-01-29",{"date":62,"type":32},"2026-02-02",{"date":64,"type":32},"2025-08-28",{"date":66,"type":19},"2029-06-30",{"name":68,"class":39},"University of Pittsburgh",2,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":20,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":40},"100592716","creation-of-arteriovenous-fistulas-for-hemodialysis-using-the-end-to-side-anastomotic-technique-vs-piggyback-100592716","NCT06997042","Creation of Arteriovenous Fistulas for Hemodialysis Using the End-to-side Anastomotic Technique vs. Piggyback.","Creation of Arteriovenous Fistulas for Hemodialysis Using the End-to-side Anastomotic Technique vs. Piggyback. Randomized Clinical Trial","Inclusion Criteria:\n\n* Age \\> 18 years\n* Able to meet protocol requirements, including follow-up.\n* Incident or prevalent patient with advanced chronic kidney disease in the hemodialysis stage (stage 5D).\n* In predialysis patients (stage 5), if renal replacement therapy (hemodialysis) is anticipated to be required within the next 6 months (based on standard clinical criteria).\n* Who, based on their associated pathology and according to medical criteria, can withstand the initial surgery and arteriovenous access maintenance procedures.\n* Have a current ultrasound with preoperative venous and arterial mapping.\n* Meet the anatomical requirements for AVF creation:\n\n  * Wrist: artery \\>2 mm, vein \\>2 mm in diameter\n  * Elbow: artery \\>3 mm, vein \\>3 mm in diameter\n  * Absence of arterial calcification or occlusion, or other aberrant arterial anatomy.\n  * Adequate arterial and venous patency.\n  * Vein-to-skin distance \\\u003C5 mm.\n* Candidate for creation of a native arteriovenous fistula for hemodialysis, either distal (radiocephalic) or proximal (humerocephalic or humerobasilic).\n* No immediate transplant scheduled within the next 60 days (inclusion on the kidney transplant waiting list is not a contraindication for entry into the study, nor for the creation of an arteriovenous fistula).\n* No prior arteriovenous surgeries in the same or proximal location.\n* Correct understanding of the study conditions and acceptance to participate.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Life expectancy \\\u003C1 year.\n* Arteriovenous prostheses (non-native fistulas), previous arteriovenous fistula repairs, arteriovenous accesses created in the lower extremities, and unusual (exotic) accesses.\n* Known or suspected central venous stenosis\u002Focclusion on the side of the planned access.\n* Repair of previous arteriovenous accesses (proximal reanastomoses).\n* Biological immunosuppression.\n* History or evidence of serious systemic illness, including:\n\n  * Cardiac disease (New York Heart Association functional class III or IV, as evidenced by the inability to lie still), myocardial infarction within 6 weeks prior to randomization, ventricular tachyarrhythmia requiring ongoing treatment, or unstable angina.\n\nSuspected or documented hypercoagulable or hypocoagulable state or Clinically significant active infection (White blood count \\> 15,000 cells\u002Fmm3) other than the use of a treated CVC.\n\n* Any other condition that, in the investigator's judgment, prevents an adequate evaluation of the safety and efficacy of the study or poor compliance.\n* Patient unwilling or unable to attend follow-up follow-ups.",{"count":78,"type":19},130,[22],"This study is designed to compare two surgical techniques used to create arteriovenous fistulas (AVFs), which are necessary for hemodialysis in patients with advanced chronic kidney disease (CKD). AVFs are preferred over other forms of vascular access because they last longer and have fewer complications. However, many AVFs fail to mature properly, making them unusable for dialysis.\n\nThe two techniques being studied are the traditional End-to-Side (ETS) method and a newer technique called Piggyback Straight Line Onlay Technique (pSLOT). Early studies suggest that pSLOT may reduce complications like narrowing (stenosis), clotting (thrombosis), and failure of the AVF, but more robust data from randomized clinical trials is needed.\n\nPatients aged 18 or older with stage 4 or 5 CKD, who are eligible for a new AVF and meet health criteria, may participate. During the operation, participants are randomly assigned to receive either the ETS or pSLOT technique. The procedure is done under local or regional anesthesia. Follow-up appointments are scheduled at 1 and 12 months to assess fistula maturation, blood flow, and whether it can be successfully used for dialysis. Remote follow-ups are allowed if needed.\n\nParticipation is voluntary, requires informed consent, and all data is kept strictly confidential. The study follows national and international ethical standards and has been approved by an ethics committee.",[25],[83,84,85,86],"hemodialysis","vascular access","arteriovenous fistula","piggyback","2025-09-12",{"date":89,"type":32},"2025-09-18",{"date":91,"type":32},"2025-05-01",{"date":93,"type":19},"2027-12-01",{"name":95,"class":39},"Hospital Clinic of Barcelona",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":15,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":20,"phases":107,"briefSummary":108,"conditions":109,"keywords":116,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":40},"100566830","dialysis-with-expanded-solute-removal-100566830","NCT06660277","DIALysis With EXpanded Solute Removal","DIALysis With EXpanded Solute Removal (DIALEX): A Large, Simple Randomized Trial to Evaluate the Major Health Effects of Expanded Versus Conventional Hemodialysis.","DIALEX","Inclusion Criteria: Inclusion requires that all the following are present:\n\n1. One of:\n\n   1. Age 60 years or older; or\n   2. Age 45 to 59 years with a history of diabetes mellitus (Type 1 or Type 2) regardless of current glycemic status; and\n2. Receiving any form of dialysis regularly for the previous 90 days; and\n3. Currently receiving HD in-centre (main or satellite unit) 3 or more times per week; and\n4. A valid provincial or territorial health insurance card number.\n\nExclusion Criteria: Patients are ineligible if they meet any of the following criteria:\n\n1. Not appropriate for this study in the opinion of the treating nephrologist or dialysis nurse practitioner due to any of:\n\n   1. Known or anticipated intolerance to the Nipro Elisio HX dialyzer; or\n   2. Planned to receive HDF; or\n   3. Planned to receive nocturnal HD; or\n   4. Anticipated to discontinue in-centre HD in the next 3 months for any reason (examples: palliation, transplantation, home dialysis, recovery of kidney function, death, others); or\n   5. Anticipated severe non-adherence to the frequency or duration of prescribed dialysis treatment; or\n   6. An overriding clinical preference for expanded HD (i.e., dialysis with the Elisio HX or other comparable dialyzer, such as Baxter TheranovaTM); or\n   7. Another medical, psychosocial, or logistical reason; or\n2. Enrolled in another clinical trial that explicitly prohibits concurrent participation in other clinical trials or that would substantially interfere with adherence to the DIALEX procedures (note that DIALEX otherwise permits concurrent participation in other trials); or\n3. Previously enrolled in this trial; or\n4. Declined participation.","45 Years",{"count":106,"type":19},4800,[22],"The goal of this clinical trial is to evaluate the health effects of expanded hemodialysis in patients receiving hemodialysis. The main question it aims to answer is:\n\n1\\) Does expanded hemodialysis reduce the risk of death from any cause?\n\nResearchers will compare expanded hemodialysis to conventional hemodialysis (the treatment currently used for the majority of patients receiving hemodialysis) to see if expanded hemodialysis works to improve patient outcomes.\n\nParticipants will continue to receive their regularly scheduled hemodialysis treatments using either a super high-flux\u002Fexpanded dialysis filter or a high-flux\u002Fconventional dialysis filter. All other aspects of treatments remain the same. No additional tests or visits are required. Data will be obtained using administrative healthcare databases and medical record review (at a subset of participating locations).",[25,110,111,112,113,114,115,56],"End-Stage Kidney Disease (ESKD)","Chronic Kidney Disease Requiring Chronic Dialysis","Pragmatic Randomized Controlled Trial","Kidney Disease","Renal Insufficiency, Chronic","Kidney Failure, Chronic",[117,118,119,120,121,122,123],"Nipro Elisio HX","RCT","Dialyzer","Hemodialysis Filter","Super-High Flux Dialyzer","High-Flux Dialyzer","Expanded Hemodialysis","2025-08-22",{"date":64,"type":32},{"date":127,"type":32},"2025-08-12",{"date":129,"type":19},"2030-08",{"name":131,"class":39},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":15,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":20,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":69},"100596408","aerobic-versus-resistive-intradialytic-training-effect-on-atherogeinc-index-in-hemodialysis-patients-100596408","NCT07045064","Aerobic Versus Resistive Intradialytic Training Effect on Atherogeinc Index in Hemodialysis Patients","Inclusion Criteria:\n\n.Maintenance hemodialysis ≥ 3 months. .BMI will be ranged from 18.5 to 29.9 kg\u002Fm². .Age ≥ 40years and ≤ 60 years. .Hemodialysis 3 times a week.\n\nExclusion Criteria:\n\n.patients suffered from any central and peripheral nervous system diseases. .patients suffered from serious complications, such as heart failure, severe infection and malignant tumor.\n\n.uncontrolled hypertension with systolic blood pressure ⩾200 mm Hg and\u002For diastolic blood pressure ⩾120 mm Hg.\n\n.unstable angina","40 Years","60 Years",{"count":141,"type":19},60,[22],"the goal of the clinical trial is to study the effect of aerobic and resistive exercises on atherogenic index in hemodialysis patients the study will include three groups of both sex the first group will participate in aerobic exercise ,the second group will participate in resistive exercise and the third group will be control group",[25],"2025-07-03",{"date":147,"type":32},"2025-07-09",{"date":149,"type":32},"2025-07-04",{"date":151,"type":19},"2026-03",{"name":153,"class":39},"Cairo University",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":20,"phases":163,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":5},"100597101","efficacy-of-live-online-course-mindfulness-program-on-perceived-fatigue-in-hemodialysis-patients-100597101","NCT07054112","Efficacy of Live Online Course Mindfulness Program on Perceived Fatigue in Hemodialysis Patients","MEDIA","Inclusion Criteria:\n\n* Age \\>= 18 years old\n* Written informed consent obtained from the participant\n* Patients on chronic hemodialysis for more than 3 months\n* Participant affiliated to social security system\n* Internet access\n* Patient motivation\u002Fcommitment\n* Patient having 3 days of dialysis per week\n\nExclusion Criteria:\n\n* Major acute depression\n* Patient on peritoneal dialysis\n* Already participated in an MBSR program\n* Patients covered by articles L1121-5 to L1121-8 of the French Public Health Code (corresponding to protected persons: pregnant women, women who have recently given birth or are breastfeeding, persons deprived of their rights by judicial or administrative decision, minors, and persons benefiting from legal protection: curatorship or guardianship).\n* Planned hospitalization within 4 months\n* Known cognitive disorder (Mini Mental State Evaluation \\\u003C23 for more than 65 years)\n* Known schizophrenia\n* Known psychotic personality disorder\n* Suicide attempt or suicidal ideation\n* Addiction to alcohol or drugs during addiction treatment\n* Cancer undergoing chemotherapy\n* Pathological grieving process\n* Compulsive eating disorders\n* No understanding of French\n* Unaided deafness",{"count":162,"type":19},80,[22],"The goal of this clinical trial is to assess the efficacy of a 2-month live online mindfulness meditation program in reducing perceived fatigue (measured by the SONG-HD Fatigue Scale) in patients undergoing chronic hemodialysis.\n\nThe sponsor expects that a live online mindfulness meditation course will have a significant public health impact by reducing perceived fatigue, which is strongly associated with cardiovascular events, mortality, and reduced quality of life.\n\nParticipants will be enrolled according to eligibility criteria and randomized into one of the following groups:\n\nExperimental group: will receive an 8-week live online Mindfulness-Based Stress Reduction (MBSR) program.\n\nControl group: will receive standard care during their hemodialysis sessions and will be offered the same live online MBSR program between months 8 and 10.\n\nPatients will complete self-administered questionnaires at baseline, 2 months, 8 months, and 10 months to monitor changes in fatigue, anxiety, and quality of life.",[25],[167,168,169,170],"chronic kidney desease","MBSR program","fatigue","Song scale","NOT_YET_RECRUITING","2025-07-02",{"date":174,"type":32},"2025-07-08",{"date":176,"type":19},"2025-09-30",{"date":178,"type":19},"2027-07-30",{"name":180,"class":39},"University Hospital, Tours",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":20,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":40},"100581194","effect-of-zinc-supplementation-on-hyperhomocysteinemia-compared-to-folic-acid-in-ckd-patient-on-hemodialysis-100581194","NCT06847139","Effect of Zinc Supplementation on Hyperhomocysteinemia Compared to Folic Acid in CKD Patient on Hemodialysis","Effect of Zinc Supplementation on Hyperhomocysteinemia Compared to That of Folic Acid in Patients of Chronic Kidney Disease on Hemodialysis-A Randomized Controlled Trial.","CKD","Inclusion Criteria:\n\n* 1\\. Age ≥18 years 2. Patient with chronic kidney disease on HD for ≥ 3 months 3. Plasma homocysteine level \\> 15μmol\u002FL\n\nExclusion Criteria:\n\n1. Acute illness at the time of inclusion.\n2. Diagnosed case of malabsorption\n3. Planned major surgery\n4. Renal transplantation\n5. Receiving zinc or folic acid supplementation within the previous month from enrollment.\n6. Concomitant use of vitamin B 12 supplementation(6 days), corticosteroid (18-36 hour), anti folate or cytotoxic drugs, quinolones, tetracyclines, bisphosphonates.\n7. Known hypersensitivity to zinc or folic acid.\n\n   \\-",{"count":190,"type":19},90,[22],"Hyperhomocysteinemia is a well-recognized risk factor for accelerated cardiovascular events in hemodialysis patients. Hyperhomocysteinemia is common in individuals with chronic kidney disease (CKD). Zinc is a vital cofactor for homocysteine metabolism enzymes. Although numerous studies have demonstrated the efficacy of folic acid in hyperhomocysteinemia, zinc supplementation has the potential to reduce homocysteine levels in hemodialysis patients. Objective: To evaluate the effect of Zinc supplementation on hyperhomocysteinemia compared to that of folic acid in patients with chronic kidney disease on hemodialysis. Materials and Methods: This open-label randomized active-controlled trial will be conducted in the Department of Nephrology of Chittagong Medical College Hospital, Chattogram, Bangladesh, for one and a half years. A total of ninety CKD patients on maintenance hemodialysis will be included in the study. Patients will be randomly divided into two groups. The experimental group will be treated with zinc sulfate (50 mg elemental zinc\u002Fday) for six weeks in conjunction with conventional treatment for CKD. The Control group will receive folic acid (5mg\u002Fday) along with conventional medications for CKD. The primary outcome measure will be the change in the plasma homocysteine level after 6 weeks, while the other variables will include serum creatinine, eGFR, serum albumin and C-reactive protein (CRP) level. Adverse events and safety measures will also be recorded. The primary analysis will be an intention to treat analysis performed with SPSS-23. Data from previous studies indicate zinc supplementation can reduce homocysteine levels in CKD patients facilitating its metabolism. Additionally, the anti-inflammatory properties of zinc may facilitate homocysteine reduction. Moreover, zinc is crucial in various physiological processes, including immune function, protein synthesis, and wound healing. Further clinical trials are still needed to understand better the safety and efficacy of zinc supplementation in CKD patients.",[25],"2025-05-22",{"date":196,"type":32},"2025-05-23",{"date":198,"type":32},"2024-07-01",{"date":200,"type":19},"2025-10-30",{"name":202,"class":39},"Chittagong Medical College",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":20,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":40},"100589891","effect-of-a-structured-physical-exercise-program-on-arteriovenous-fistula-maturation-for-hemodialysis-in-chronic-kidney-disease-patients-100589891","NCT06960304","Effect of a Structured Physical Exercise Program on Arteriovenous Fistula Maturation for Hemodialysis in Chronic Kidney Disease Patients","PEFAV","Inclusion Criteria:\n\n* Age ≥ 18 years\n* AVF in the upper limb\n* No cognitive decline and ability to follow instructions\n\nExclusion Criteria:\n\n* History of previous dysfunctional ipsilateral AVF\n* History of injury\u002Fcondition causing pain or loss of function in the AVF limb\n* Musculoskeletal conditions\u002Fosteoarticular pathology (e.g., myopathy, rheumatoid arthritis)\n* Neurological conditions\u002Fcardiovascular events (e.g., stroke, peripheral neuropathy",{"count":211,"type":19},128,[22],"For patients living with Chronic Kidney Disease who are preparing to start hemodialysis, having a well-functioning arteriovenous fistula (AVF) is essential. Although the AVF is considered the best type of vascular access, its maturation process does not always go as expected-studies show that in 28% to 53% of cases, the fistula does not mature properly, making effective dialysis more difficult. There is growing interest in using physical exercise as a way to support AVF maturation. International guidelines even recommend arm exercises for this purpose. However, there is still no clear agreement on what type of exercise, how often, or how intense it should be. This study aims to evaluate whether a structured exercise program focused on the AVF arm can help improve the fistula's development and overall function.",[25],[216,217,83,218],"physical exercise","chronic kidney disease","fistula maturation","2025-05-05",{"date":221,"type":32},"2025-05-07",{"date":223,"type":32},"2025-01-16",{"date":225,"type":19},"2026-06-30",{"name":227,"class":39},"Unidade Local de Saúde de Coimbra, EPE",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":20,"phases":237,"briefSummary":239,"conditions":240,"keywords":241,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":40},"100587498","phase-2-cardiovascular-effects-of-sglt2-inhibitors-in-hemodialysis-patients-a-phase-2-randomized-study-100587498","NCT06929169","Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study","SGLT2-HD","Inclusion Criteria:\n\n* Age ≥18 and ≤70 years\n* Diagnosed with end-stage renal disease\n* Undergoing online hemodiafiltration for at least 3 months\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Current immunosuppressive therapy\n* Contraindication to cardiac MRI\n* Known hypersensitivity or intolerance to SGLT2 inhibitors\n* Participation in another interventional clinical trial\n* History of diabetic ketoacidosis\n* Active substance abuse\n* Diagnosis of type 1 diabetes mellitus\n* History of kidney transplantation\n* Acute coronary event within 30 days before enrollment\n* Current or recent treatment with an SGLT2 inhibitor","70 Years",{"count":162,"type":19},[238],"PHASE2","Patients with end-stage kidney disease (ESKD) on hemodialysis face an unacceptably high rate of cardiovascular complications, including heart failure, arrhythmias, and sudden cardiac death. Many of these outcomes are driven by diastolic dysfunction and cardiac fibrosis-conditions that are not adequately addressed by current therapies. SGLT2 inhibitors, originally developed for the treatment of type 2 diabetes, have demonstrated cardiovascular and renal protective effects across multiple patient populations, independent of glycemic control.\n\nThis Phase 2, randomized, controlled clinical trial will evaluate the safety and efficacy of SGLT2 inhibitors in patients undergoing maintenance hemodialysis. A total of 80 participants will be randomized to receive either an SGLT2 inhibitor or standard care for 12 months. The primary objective is to determine whether SGLT2 inhibitors improve cardiac function, reduce myocardial fibrosis, and decrease the incidence of intradialytic hypotension. Secondary endpoints include cardiovascular events, hospitalization, and all-cause mortality. The study will also assess changes in key biomarkers and perform advanced cardiac imaging to evaluate structural and functional outcomes.\n\nThis trial represents a novel and timely investigation into a class of medications with promising pleiotropic effects, potentially offering new therapeutic options for a high-risk, underserved population.",[25],[242,56,243,244,245,246,247,55],"SGLT2 Inhibitors","Cardiac MRI","Ventricular Remodeling","Heart Failure with Preserved Ejection Fraction","Myocardial Fibrosis","Cardiovascular Disease","2025-04-08",{"date":250,"type":32},"2025-04-16",{"date":252,"type":19},"2025-05",{"date":254,"type":19},"2026-08",{"name":256,"class":39},"Maximo Agustin Schiavone",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":266,"phases":4,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":4},"100575414","ultrasound-prediction-of-successful-balloon-assisted-avf-maturation-100575414","NCT06771973","Ultrasound Prediction of Successful Balloon Assisted AVF Maturation","A Prospective Cohort Study Analysing Prediction of Successful Arteriovenous Fistula (AVF) Maturation Post Balloon Assisted Fistuloplasty With Duplex Ultrasound and Inflammatory Biomarkers","Inclusion Criteria:\n\n* Adult patients (\\>18 years of age) referred for BAM procedure due to immature native AVF\n* AVFs with radio-cephalic or brachio-cephalic configuration\n* AVF suitable for endovascular BAM procedure\n* Patient is able to provide informed consent\n* Patient is willing and able to comply with the study-related procedures\n\nExclusion Criteria:\n\n* Brachio-basilic AVFs requiring transposition and superficialisation procedures during maturation phase\n* Patients with arterio-venous grafts (AVGs) for vascular access\n* Previous BAM procedures performed to facilitate maturation\n* AVF unsuitable for BAM procedure or BAM procedure not performed",{"count":265,"type":19},40,"OBSERVATIONAL","An arteriovenous fistula (AVF) is created to allow for cleaning of the blood in patients with severe kidney disease. An artery and a vein are surgically connected, typically in the arm. This connection changes how the blood flows through the vessels, creating much higher flow in the arm vein than before the operation. Higher blood flow enables blood flow to be cleaned externally with a machine replacing the function of the kidneys. This process is known as dialysis. However, a period known as maturation is required before an AVF can be used in this way. During this time, the vessels grow in size and blood flow continues to increase. In some cases this does not happen and a procedure is required to help the AVF to mature.\n\nAVFs not likely to mature may undergo a procedure, known as balloon assisted maturation (BAM), in which a balloon on the end of a catheter is inserted into the AVF vein and inflated. This is typically needed if an AVF is not likely to develop in a way that can be used for dialysis. Blood cleaning, or haemodialysis, is vital in patients with end stage renal disease, or kidney failure. Blood flow measurement using ultrasound, and routine blood test results, may help us predict which AVFs will respond better to BAM. Ultrasound can be used in the clinic setting and can provide the consultants responsible for the patients ongoing management with information that can enable decisions to be made at an early opportunity, and allowing the participants to be involved in future management decisions. This study aims to identify features of the blood flow following the BAM procedure that might be used to predict if the AVF will successfully mature.",[269,25],"End Stage Renal Disease (ESRD)",[85,271,187,272],"AVF","ESRD","2025-01-14",{"date":275,"type":32},"2025-01-15",{"date":277,"type":19},"2025-01-13",{"date":279,"type":19},"2026-04-01",{"name":281,"class":39},"Guy's and St Thomas' NHS Foundation Trust"]